Probing ligand-specific histamine H1- and H2-receptor conformations with NG-acylated imidazolylpropylguanidines

Sheng Xue Xie, Prasanta Ghorai, Qizhuang Ye, Armin Buschauer, Roland Seifert

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Impromidine (IMP) and arpromidine (ARP)-derived guanidines are more potent and efficacious guinea pig (gp) histamine H2-receptor (gpH 2R) than human (h) H2R agonists and histamine H 1-receptor (H1R) antagonists with preference for hH 1R relative to gpH1R. We examined NG-acylated imidazolylpropylguanidines (AIPGs), which are less basic than guanidines, at hH2R, gpH2R, rat H2R (rH2R), hH 1R, and gpH1R expressed in Sf9 cells as probes for ligand-specific receptor conformations. AIPGs were similarly potent H 2R agonists as the corresponding guanidines IMP and ARP, respectively. Exchange of pyridyl in ARP against phenyl increased AIPG potency 10-fold, yielding the most potent agonists at the hH 2R-G fusion protein and gpH2R-G identified so far. Some AIPGs were similarly potent and efficacious at hH 2R-G and gpH2R-G. AIPGs stabilized the ternary complex in hH2R-G and gpH2R-G differently than the corresponding guanidines. Guanidines, AIPGs, and small H2R agonists exhibited distinct agonist properties at hH2R, gpH2R, and rH 2R measuring adenylyl cyclase activity. In contrast to ARP and IMP, AIPGs were partial H1R agonists exhibiting higher efficacies at hH1R than at gpH1R. This is remarkable because, so far, all bulky H1R agonists exhibited higher efficacies at gpH 1R than at hH1R. Collectively, our data suggest that AIPGs stabilize different active conformations in hH2R, gpH2R, and rH2R than guanidines and that, in contrast to guanidines, AIPGs are capable of stabilizing a partially active state of hH1R.

Original languageEnglish (US)
Pages (from-to)139-146
Number of pages8
JournalJournal of Pharmacology and Experimental Therapeutics
Volume317
Issue number1
DOIs
StatePublished - Apr 2006
Externally publishedYes

Fingerprint

Guanidines
Histamine H1 Receptors
Histamine H2 Receptors
Impromidine
Ligands
Histamine Agonists
Sf9 Cells
Adenylyl Cyclases
Guinea Pigs
arpromidine

ASJC Scopus subject areas

  • Pharmacology

Cite this

Probing ligand-specific histamine H1- and H2-receptor conformations with NG-acylated imidazolylpropylguanidines. / Xie, Sheng Xue; Ghorai, Prasanta; Ye, Qizhuang; Buschauer, Armin; Seifert, Roland.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 317, No. 1, 04.2006, p. 139-146.

Research output: Contribution to journalArticle

@article{5fbd2f677c604fc2a32bf26a6483e9c2,
title = "Probing ligand-specific histamine H1- and H2-receptor conformations with NG-acylated imidazolylpropylguanidines",
abstract = "Impromidine (IMP) and arpromidine (ARP)-derived guanidines are more potent and efficacious guinea pig (gp) histamine H2-receptor (gpH 2R) than human (h) H2R agonists and histamine H 1-receptor (H1R) antagonists with preference for hH 1R relative to gpH1R. We examined NG-acylated imidazolylpropylguanidines (AIPGs), which are less basic than guanidines, at hH2R, gpH2R, rat H2R (rH2R), hH 1R, and gpH1R expressed in Sf9 cells as probes for ligand-specific receptor conformations. AIPGs were similarly potent H 2R agonists as the corresponding guanidines IMP and ARP, respectively. Exchange of pyridyl in ARP against phenyl increased AIPG potency 10-fold, yielding the most potent agonists at the hH 2R-G sα fusion protein and gpH2R-Gsα identified so far. Some AIPGs were similarly potent and efficacious at hH 2R-Gsα and gpH2R-Gsα. AIPGs stabilized the ternary complex in hH2R-Gsα and gpH2R-Gsα differently than the corresponding guanidines. Guanidines, AIPGs, and small H2R agonists exhibited distinct agonist properties at hH2R, gpH2R, and rH 2R measuring adenylyl cyclase activity. In contrast to ARP and IMP, AIPGs were partial H1R agonists exhibiting higher efficacies at hH1R than at gpH1R. This is remarkable because, so far, all bulky H1R agonists exhibited higher efficacies at gpH 1R than at hH1R. Collectively, our data suggest that AIPGs stabilize different active conformations in hH2R, gpH2R, and rH2R than guanidines and that, in contrast to guanidines, AIPGs are capable of stabilizing a partially active state of hH1R.",
author = "Xie, {Sheng Xue} and Prasanta Ghorai and Qizhuang Ye and Armin Buschauer and Roland Seifert",
year = "2006",
month = "4",
doi = "10.1124/jpet.105.097923",
language = "English (US)",
volume = "317",
pages = "139--146",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Probing ligand-specific histamine H1- and H2-receptor conformations with NG-acylated imidazolylpropylguanidines

AU - Xie, Sheng Xue

AU - Ghorai, Prasanta

AU - Ye, Qizhuang

AU - Buschauer, Armin

AU - Seifert, Roland

PY - 2006/4

Y1 - 2006/4

N2 - Impromidine (IMP) and arpromidine (ARP)-derived guanidines are more potent and efficacious guinea pig (gp) histamine H2-receptor (gpH 2R) than human (h) H2R agonists and histamine H 1-receptor (H1R) antagonists with preference for hH 1R relative to gpH1R. We examined NG-acylated imidazolylpropylguanidines (AIPGs), which are less basic than guanidines, at hH2R, gpH2R, rat H2R (rH2R), hH 1R, and gpH1R expressed in Sf9 cells as probes for ligand-specific receptor conformations. AIPGs were similarly potent H 2R agonists as the corresponding guanidines IMP and ARP, respectively. Exchange of pyridyl in ARP against phenyl increased AIPG potency 10-fold, yielding the most potent agonists at the hH 2R-G sα fusion protein and gpH2R-Gsα identified so far. Some AIPGs were similarly potent and efficacious at hH 2R-Gsα and gpH2R-Gsα. AIPGs stabilized the ternary complex in hH2R-Gsα and gpH2R-Gsα differently than the corresponding guanidines. Guanidines, AIPGs, and small H2R agonists exhibited distinct agonist properties at hH2R, gpH2R, and rH 2R measuring adenylyl cyclase activity. In contrast to ARP and IMP, AIPGs were partial H1R agonists exhibiting higher efficacies at hH1R than at gpH1R. This is remarkable because, so far, all bulky H1R agonists exhibited higher efficacies at gpH 1R than at hH1R. Collectively, our data suggest that AIPGs stabilize different active conformations in hH2R, gpH2R, and rH2R than guanidines and that, in contrast to guanidines, AIPGs are capable of stabilizing a partially active state of hH1R.

AB - Impromidine (IMP) and arpromidine (ARP)-derived guanidines are more potent and efficacious guinea pig (gp) histamine H2-receptor (gpH 2R) than human (h) H2R agonists and histamine H 1-receptor (H1R) antagonists with preference for hH 1R relative to gpH1R. We examined NG-acylated imidazolylpropylguanidines (AIPGs), which are less basic than guanidines, at hH2R, gpH2R, rat H2R (rH2R), hH 1R, and gpH1R expressed in Sf9 cells as probes for ligand-specific receptor conformations. AIPGs were similarly potent H 2R agonists as the corresponding guanidines IMP and ARP, respectively. Exchange of pyridyl in ARP against phenyl increased AIPG potency 10-fold, yielding the most potent agonists at the hH 2R-G sα fusion protein and gpH2R-Gsα identified so far. Some AIPGs were similarly potent and efficacious at hH 2R-Gsα and gpH2R-Gsα. AIPGs stabilized the ternary complex in hH2R-Gsα and gpH2R-Gsα differently than the corresponding guanidines. Guanidines, AIPGs, and small H2R agonists exhibited distinct agonist properties at hH2R, gpH2R, and rH 2R measuring adenylyl cyclase activity. In contrast to ARP and IMP, AIPGs were partial H1R agonists exhibiting higher efficacies at hH1R than at gpH1R. This is remarkable because, so far, all bulky H1R agonists exhibited higher efficacies at gpH 1R than at hH1R. Collectively, our data suggest that AIPGs stabilize different active conformations in hH2R, gpH2R, and rH2R than guanidines and that, in contrast to guanidines, AIPGs are capable of stabilizing a partially active state of hH1R.

UR - http://www.scopus.com/inward/record.url?scp=33645114357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645114357&partnerID=8YFLogxK

U2 - 10.1124/jpet.105.097923

DO - 10.1124/jpet.105.097923

M3 - Article

VL - 317

SP - 139

EP - 146

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 1

ER -